Novartis Presentations at the 2022 ASCO Annual Meeting
As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
Alpelisib (Abstract # 1006)
Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study
D. Juric
Alpelisib (Abstract # 1018)
Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study
D. Juric
Alpelisib (Abstract # 1055)
Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) after prior treatment (tx) with FUL in patients (pts) with advanced breast cancer (ABC): A real-world (RW) analysis
J. O'Shaughnessy
Alpelisib (Abstract # TPS1107)
EPIK-B4: A phase 2, randomized study of metformin (MET) extended release (XR) +/- dapagliflozin (DAPA) to prevent hyperglycemia (HG) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC) treated with alpelisib (ALP) and fulvestrant (FUL)
W. Gradishar
Alpelisib (Abstract # TPS1109)
EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i)
M. De Laurentiis
Ribociclib (Abstract # 1012)
Circulating tumor DNA (ctDNA) and serum thymidine kinase 1 activity (TKa) matched dynamics in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor 2–negative (HER2-) advanced breast cancer (ABC) treated in first-line (1L) with ribociclib (RIB) and letrozole (LET) in the BioItaLEE trial
G. Arpino
Ribociclib (Abstract # 1015)
Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor–negative (HR+/HER2−) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC)
H. Rugo
Ribociclib (Abstract # 1017)
Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2- advanced breast cancer (ABC) in MONALEESA (ML)-2
L. Hart
Ribociclib (Abstract # 1065)
Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Results of fourth interim analysis (IA) from RIBANNA
D. Lüftner
As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
NIS793 (Abstract # TPS4183)
Phase II study (daNIS-1) of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)
L. Y. Bai
NIS793 (Abstract # TPS4193)
Phase III study (daNIS-2) of the anti–TGF-β monoclonal antibody (mAb) NIS793 with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)
E. M. O'Reilly
As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
Canakinumab (Abstract # e20569)
Retrospective study to examine prognostic value of c-reactive protein (CRP) in patients with surgically resected non-small-cell lung cancer (NSCLC)
G. Azzoli
Capmatinib (Abstract # 9118)
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study
T. Mok
Capmatinib (Abstract # TPS8590)
Neoadjuvant and adjuvant capmatinib in resectable non–small cell lung cancer with MET exon 14 skipping mutation or high MET amplification: GEOMETRY-N trial
J. M. Lee
Capmatinib (Abstract # TPS9153)
Capmatinib plus osimertinibversus platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIb/IIIc or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification
Y. L. Wu
Capmatinib (Abstract # e21171)
Real-world assessment of clinical outcomes in NSCLC patients with MET exon 14 skipping mutation and brain metastases (BM) treated with capmatinib
P. Paik
Dabrafenib (Abstract # 9082)
Efficacy of dabrafenib-trametinib combination in BRAFV600E-mutated metastatic non–small cell lung cancer: Results of the IFCT-2004 BLaDE cohort
A. Swalduz
As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
Dabrafenib-Trametinib (Abstract # 9531)
Progression and mortality post-immunotherapy discontinuation among patients with BRAFV600-mutant (BRAF+) metastatic melanoma
S. Chandra
Dabrafenib-Trametinib (Abstract # 9532)
Real-world evaluation of the association between baseline metastatic patterns and clinical outcomes among patients with BRAF-positive metastatic melanoma
Z. Eroglu
Dabrafenib-Trametinib (Abstract # 9563)
Adjuvant dabrafenib plus trametinib (D + T) versus placebo in patients with resected stage III BRAF V600-mutant melanoma: Updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD
D. Schadendorf
Spartalizumab (Abstract # 9527)
Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial
R. Dummer
As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
177Lu-DOTATATE (Abstract # e16215)
Effectiveness and safety of retreatment with lutetium Lu 177 DOTATATE in patients with progressive neuroendocrine tumors in the United States: A retrospective real-world study
E. Delpassand
As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
[68Ga]Ga-PSMA-11 (Abstract # 5002)
[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy
P. Kuo
177Lu-PSMA-617 (Abstract # 5001)
[177Lu]Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial
N. Vaishampayan
177Lu-PSMA-617 (Abstract # 5047)
Tolerability of [177Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis
S. Tagawa
Real-World Evidence (Abstract # e17024)
Real-world treatment patterns in the U.S. and trends pre-post CARD trial among patients with metastatic castration-resistant prostate cancer
S. Ghantoji
As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
Advanced Malignancies
Advanced Malignancies
MAK683 (Abstract # 3083)
Pharmacokinetic and pharmacodynamic activity evaluation of MAK683, a selective oral embryonic ectoderm development (EED) inhibitor, in adults with advanced malignancies in a first-in-human study
V. Ribrag
Chronic Myeloid Leukemia (CML)
Chronic Myeloid Leukemia (CML)
Asciminib (Abstract # 7004)
Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update
D. Rea
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
Tislelizumab (Abstract # e16042)
Real-world treatment patterns and survival of U.S. patients receiving second-line anti-programmed cell death protein-1 therapy for advanced/metastatic esophageal squamous cell carcinoma
D. Ahn
Glioma
Glioma
Trametinib (Abstract # LBA2002)
Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in BRAF V600–mutant pediatric low-grade glioma (pLGG)
E. Bouffet
Trametinib (Abstract # 2009)
Dabrafenib + trametinib (dab + tram) in relapsed/refractory (r/r) BRAF V600–mutant pediatric high-grade glioma (pHGG): Primary analysis of a phase II trial
D. Hargrave
PIK3CA-Related Overgrowth Spectrum (PROS)
PIK3CA-Related Overgrowth Spectrum (PROS)
Alpelisib (Abstract # e18694)
Alpelisib(ALP), a breast cancer therapy, for PIK3CA-related overgrowth spectrum (PROS): A real-world data approach to a rare disease indication
D. Adams
Alpelisib (Abstract # e18707)
Understanding the path to diagnosis and clinical presentation of patients with PIK3CA-related overgrowth spectrum (PROS) through an innovative patient-centered data platform
D. Adams
Renal Cell Carcinoma
Renal Cell Carcinoma
Pazopanib (Abstract # e16511)
Impact of trial-eligibility as factor for clinical outcome of patients with renal cell carcinoma treated with first-line pazopanib: Subgroup analysis from the prospective, non-interventional study PAZOREAL
M. Schostak
